bioRxivCancer BiologyPreprint
SIX4 Controls STING Expression Enhancing anti-PD-1 Efficacy
B. Liang, E. H. Zhang, Z. Ye, H. Storts, W. Jin, X. Zheng, O. Zaleski, X. Xing, J. J. Wang
Abstract
The cGAS/STING cytosolic DNA sensing pathway plays a central role in anti-tumor immunity. Expression of STING is tightly regulated and commonly reduced or defective in many types of cancer. We have identified SIX4 as a significant regulator of STING expression in colon cancer cells. We showed that knockout of SIX4 decreased STING expression at the mRNA and protein levels while ectopic expression of SIX4 increased STING expression. Depletion of SIX4 led to attenuated STING activation and downstream signaling. Re-expression of SIX4 or ectopic expression of STING in SIX4 knockout cells reversed the effect. Ectopic expression of SIX4 enhanced DMXAA and cGAMP-induced STING activation and downstream signaling. Importantly, decrease of SIX4 expression substantially decreased tumor infiltration of CD8+ T-cells and reduced the efficacy of PD-1 antibodies to diminish tumor growth in immune competent mice in vivo. Finally, analysis of TCGA colon cancer dataset indicated that tumors with high SIX4 expression were significantly enriched in the Inflammatory Response pathway. SIX4 expression also correlated with expression of multiple IFN-stimulated genes, inflammatory cytokines and CD8A. Taken together, our results implicate that SIX4 is a principal regulator of STING expression in colon cancer cells, providing an additional mechanism and genetic marker to predict effective immune checkpoint blockade therapy responses.
- organism: mouse
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Low STING expression in a transplantable KrasG12D/P53ko lung cancer model contributes to SiglecF+ neutrophil and CD103+Treg accumulation in tumors
- STING Licensing of Type I Dendritic Cells Potentiates Antitumor Immunity
- Synergistic innate immune activation and anti-tumor immunity through combined STING and TLR4 stimulation
E. F. Higgs, T. F. Gajewski·bioRxiv·Apr 8, 2024
- Cancer cell-autonomous cGAS-STING response confers drug resistance
Q.-M. Lv, S.-Y. Wang, … L. Zhu·bioRxiv·Oct 23, 2021
- Cellular selectivity of STING stimulation determines priming of tumor-specific T cell responses
B. Jneid, A. Bochnakian, … N. Manel·bioRxiv·Dec 1, 2021
- cGAS/STING and NLRP3 cooperatively activate CD8+ T cell-mediated anti-tumor immunity in colorectal cancer
C. Mowat, D. Schiller, K. Baker·bioRxiv·Aug 22, 2023